A novel small‐molecule BI‐44 was synthesized, which suppressed BMI1/MCL1 expression and showed significant anti‐tumour effect in preclinical models, providing a new and promising approach for NSCLC treatment. Here, BMI1 is linked to non-small cell lung carcinoma.